Summary
When developing new medicines, scientists need to understand the underlying causes of disease. To do that, they need to be able to study in detail the role of the different proteins involved in the disease. However, that requires chemical compounds capable of altering or blocking the action of individual proteins.
The goal of EUbOPEN is to develop high quality chemical tool compounds for 1 000 human proteins. This represents around a third of the ‘druggable’ proteins in the human body. The project will test the new tools in the areas of immunology, oncology and neuroscience.
The project will make the tools, plus the accompanying data and protocols, openly available to the entire research community without restrictions on use.
By the end of the project, the EUbOPEN team will have created the largest and most deeply characterised collection of chemical modulators of protein function that is also openly accessible. Researchers in academia and industry alike will therefore be able to use the tools to study diseases, and identify proteins that play a key role in disease development and so could be targeted by drugs. The tools will also help scientists to design drugs capable of blocking specific proteins involved in diseases.
Participants
Show participants on mapEFPIA companies
- Bayer Aktiengesellschaft, Leverkusen, Germany
- Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany
- Institut De Recherches Servier, Suresnes, France
- Pfizer Limited, Sandwich, Kent , United Kingdom
- Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland
Universities, research organisations, public bodies, non-profit groups
- Academisch Ziekenhuis Leiden, Leiden, Netherlands
- Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Stiftung, Frankfurt, Germany
- Eidgenoessische Technische Hochschule Zuerich, Zurich, Switzerland
- European Molecular Biology Laboratory, Heidelberg, Germany
- Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., München, Germany
- Johann Wolfgang Goethe-Universitaet Frankfurt Am Main, Frankfurt am Main, Germany
- Karolinska Institutet, Stockholm, Sweden
- Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany
- Structural Genomics Consortium Lbg, London, United Kingdom
- The Governing Council Of The University Of Toronto, Toronto, Canada
- The University Of North Carolina At Chapel Hill, Chapel Hill, United States
- University Of Dundee, Dundee, United Kingdom
- University of Oxford, Oxford, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
- X-Chem Inc, Waltham, MA, United States
Associated partners
- Diamond Light Source Limited, Didcot, United Kingdom
- Kungliga Tekniska Hoegskolan, Stockholm, Sweden
- Ontario Institute for Cancer Research, Toronto, Ontario, Canada
- Royal Institution For The Advancement Of Learning Mcgill University, Montreal, Canada
Participants | |
---|---|
Name | EU funding in € |
Academisch Ziekenhuis Leiden | 984 901 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Stiftung | 737 754 |
Eidgenoessische Technische Hochschule Zuerich | 984 901 |
European Molecular Biology Laboratory | 331 990 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | 562 400 |
Johann Wolfgang Goethe-Universitaet Frankfurt Am Main | 7 171 503 |
Karolinska Institutet | 7 909 929 |
Ludwig-Maximilians-Universitaet Muenchen | 12 500 |
Structural Genomics Consortium Lbg | 102 059 |
University Of Dundee | 984 901 |
University of Oxford | 8 152 162 |
Total Cost | 27 935 000 |